High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. (Q54242190)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

title

High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

author

Torsten Haferlach

series ordinal

4

object named as

T Haferlach

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

author name string

N Schmitz

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

B Glass

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

P Dreger

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

H A Horst

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

J Ollech-Chwoyka

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

M Suttorp

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

W Gassmann

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

H Löffler

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

publication date

1 May 1993

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

published in

Annals of Hematology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

volume

66

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

page(s)

251-256

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

cites work

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FBF01738475

retrieved

21 January 2018

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1007%2FBF01738475

retrieved

21 January 2018

Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (AB

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose, potentially myeloablative chemotherapy and autologous bone marrow transplantation for patients with advanced Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autologous blood stem-cell transplantation in patients with advanced Hodgkin's disease and prior radiation to the pelvic site.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Development of effective salvage treatment programs for Hodgkin's disease: an ongoing clinical challenge

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The second chance for advanced Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of MOPLACE chemotherapy for patients with previously treated Hodgkin's disease: a CALGB study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/8099502

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/BF01738475

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

PubMed publication ID

8099502

1 reference

stated in

Europe PubMed Central

PubMed publication ID

8099502

retrieved

26 May 2018

reference URL

http://europepmc.org/abstract/MED/8099502

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54242190&oldid=1388249783"